CYDY Stock Price: CytoDyn Inc set to skyrocket as Phase 2 coronavirus cure trial looks promising
- OTCMKTS: CYDY stock may surge after reporting significant results from a COVID-19 cure trial.
- CytoDyn is at an advanced stage, completing Phase 2 and may enter Phase 3 with its leronlimab medication.
- Competition is fierce and attention is growing after Russia registered its first coronavirus vaccine.
CytoDyn, a biotechnology company that spans the border between Canada and the US around Vancouver and Washington, announced a promising development. Its Phase 2 trial for COVID-19 has shown significant top-line results, opening the door to conducting a broad Phase 3 trial.
The leronlimab drug helps mild to moderate COVID-19 patients, that show an improvement in clinical symptoms versus the
From the firm's announcement:
Primary endpoint shows early clinical improvement in symptom score at Day 3 in patients receiving leronlimab
Leronlimab also demonstrated statistically significant improvement versus placebo in key secondary efficacy endpoint, National Early Warning Score 2 scale (NEWS2)
Earlier in the day, Russia's President Vladimir Putin announced that his country reported the first coronavirus vaccine. However, many doubt that Moscow's announcement is based on a rigorous experiment.
cytodyn inc Stock
OTCMKTS: CYDY
Author
Yohay Elam
FXStreet
Yohay is in Forex since 2008 when he founded Forex Crunch, a blog crafted in his free time that turned into a fully-fledged currency website later sold to Finixio.
